

# **DOLPHIN MEDICAL SERVICES LIMITED**

#417, Sanali Heavens, Ameerpet, HYDERABAD – 500 073, Telangana, India

Phone/Fax:+91-40-23738877, Email: [dolphinmedicalindia@gmail.com](mailto:dolphinmedicalindia@gmail.com)

[www.dolphinmedicalsolutions.com](http://www.dolphinmedicalsolutions.com), CIN:L24239TG1992PLC014775

.....

Date: 11.11.2023

To  
The Manager  
Department of Corporate Services  
**BOMBAY STOCK EXCHANGE LTD.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

**SCRIP CODE: 526504**

Dear Sir,

**Sub: Submission of Unaudited Financial Results for the 2nd Quarter and Six months ended 30.09.2023 – Reg.**

Ref: Our letter dated 04.11.2023

With reference to the above and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith submitting Unaudited Financial Results for the 2nd Quarter and Six months ended 30.09.2023 along with the Unaudited Statement of Assets and Liabilities, Cash Flow Statement and Limited Review Report. The results were reviewed by the Audit Committee and approved and taken on record by the Board of Directors at their meeting held on 11th November 2023.

The Meeting of the Board commenced at 04.00 P.M. and concluded at 4.40 P.M.

This is for the information and records of the Exchange.

Thanking you Sir

yours faithfully,  
**for DOLPHIN MEDICAL SERVICES LIMITED**



**Dr. MOHAN PRASAD GV**  
Managing Director  
DIN: 01236113

Encls:

1. Unaudited Financial Results for the 2nd Quarter and Six months ended 30.09.2023
2. Unaudited Statement of Assets and Liabilities
3. Unaudited Cash Flow Statement
4. Limited Review Report

# DOLPHIN MEDICAL SERVICES LIMITED

#417, SANALI HEAVENS, AMEERPET, HYDERABAD - 500 073, TELANGANA

## UNAUDITED FINANCIAL RESULTS FOR THE 2ND QUARTER AND SIX MONTHS ENDED 30.09.2023

CIN: L24239TG1992PLC014775, email: dolphincomplianceofficer@gmail.com

(Prepared in compliance with the Indian Accounting Standards (Ind AS))

(Amount Rs. in Lakhs)

Sl. No.	PARTICULARS	QUARTER ENDED 30.09.2023 UNAUDITED	QUARTER ENDED 30.06.2023 UNAUDITED	QUARTER ENDED 30.09.2022 UNAUDITED	SIX MONTHS ENDED 30.09.2023 UNAUDITED	SIX MONTHS ENDED 30.09.2022 UNAUDITED	FINANCIAL YEAR ENDED 31.03.2023 AUDITED
1	<b>Revenue from Operations</b>						
	Revenue from Operations	18.24	15.27	16.47	33.51	31.32	61.12
	Other Income	0.92	0.92	0.92	1.84	1.84	3.68
	<b>Total Revenue (I + II)</b>	<b>19.16</b>	<b>16.19</b>	<b>17.39</b>	<b>35.35</b>	<b>33.16</b>	<b>64.80</b>
2	<b>Expenses</b>						
a	Cost of Materials consumed	2.59	2.16	2.36	4.75	4.45	9.16
b	Purchases of stock-in-trade	-	-	-	-	-	-
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
d	Employee benefit expense	2.10	1.70	2.03	3.80	3.87	7.19
e	Finance costs	0.24	0.24	0.24	0.48	0.46	0.93
f	Depreciation and amortisation expense	1.11	1.46	1.57	2.57	3.14	6.27
g	Other Expenses	11.81	9.37	12.51	21.18	25.13	53.01
	<b>Total Expenses</b>	<b>17.85</b>	<b>14.93</b>	<b>18.71</b>	<b>32.78</b>	<b>37.05</b>	<b>76.56</b>
3	<b>Profit/(Loss) before exceptional items and tax</b>	<b>1.31</b>	<b>1.26</b>	<b>(1.32)</b>	<b>2.57</b>	<b>(3.89)</b>	<b>(11.76)</b>
4	Exceptional items	-	-	-	-	-	-
5	<b>Profit/(Loss) before tax</b>	<b>1.31</b>	<b>1.26</b>	<b>(1.32)</b>	<b>2.57</b>	<b>(3.89)</b>	<b>(11.76)</b>
6	<b>Tax Expense</b>						
7	Current tax	-	-	-	-	-	-
8	Deferred tax	-	-	-	-	-	0.70
9	<b>Total tax expenses</b>	-	-	-	-	-	<b>0.70</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-	-	-
11	<b>Net Profit/(Loss) for the period from continuing operations</b>	<b>1.31</b>	<b>1.26</b>	<b>(1.32)</b>	<b>2.57</b>	<b>(3.89)</b>	<b>(12.46)</b>
12	Profit (loss) from discontinued operations before tax	-	-	-	-	-	-
13	Tax expense of discontinued operations	-	-	-	-	-	-
14	Net Profit/(Loss) for the period from discontinued operations after Tax	-	-	-	-	-	-
15	<b>Net Profit/(Loss) for the period</b>	<b>1.31</b>	<b>1.26</b>	<b>(1.32)</b>	<b>2.57</b>	<b>(3.89)</b>	<b>(12.46)</b>
16	Other comprehensive income net of taxes	--	--	--	--	--	--
17	<b>Total Comprehensive Income/(Loss) for the period</b>	<b>1.31</b>	<b>1.26</b>	<b>(1.32)</b>	<b>2.57</b>	<b>(3.89)</b>	<b>(12.46)</b>
18	<b>Details of equity share capital</b>						
	Paid-up equity share capital	1,509.99	1,509.99	1,509.99	1,509.99	1,509.99	1,509.99
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
19	<b>Reserves excluding revaluation reserve</b>	-	-	-	<b>(489.69)</b>	<b>(483.69)</b>	<b>(492.26)</b>
	Debenture redemption reserve	-	-	-	-	-	-
20	<b>Earnings per equity share for continuing operations</b>						
	Basic earnings (loss) per share from continuing operations	0.01	0.01	(0.01)	0.02	(0.03)	(0.08)
	Diluted earnings (loss) per share from continuing operations	0.01	0.01	(0.01)	0.02	(0.03)	(0.08)

By Order of the Board  
for DOLPHIN MEDICAL SERVICES LIMITED



Dr. MOHAN PRASAD GV  
Managing Director  
DIN: 01236113

21	<b>Earnings per equity share for discontinued operations</b>						
	Basic earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from discontinued operations	-	-	-	-	-	-
22	<b>Earnings per equity share</b>						
	Basic earnings(loss) per share from continuing and discontinued operations	0.01	0.01	(0.01)	0.02	(0.03)	(0.08)
	Diluted earnings(loss) per share from continuing and discontinued operations	0.01	0.01	(0.01)	0.02	(0.03)	(0.08)
23	Public Share Holding:						
	i) Number of Shares	1,11,07,651	1,11,07,651	1,11,07,651	1,11,07,651	1,11,07,651	1,11,07,651
	ii) Percentage of Share Holding	73.56%	73.56%	73.56%	73.56%	73.56%	73.56%
24	Promoters and Promoter group						
	Share holding						
	a) Pledged/Encumbered						
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a %age of total share holding of promoter and promoter group)	N.A	N.A	N.A	N.A	N.A	N.A
	- Percentage of shares (as a %age of total share capital of the company)	N.A	N.A	N.A	N.A	N.A	N.A
	b) Non-encumbered						
	- Number of Shares	39,92,301	39,92,301	39,92,301	39,92,301	39,92,301	39,92,301
	- Percentage of shares (as a %age of total share holding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a %age of total share capital of the company)	26.44%	26.44%	26.44%	26.44%	26.44%	26.44%

	Particulars	Quarter ended 30th September 2023
<b>B</b>	<b>Investor Complaints</b>	
1	Pending at the beginning of the Quarter	NIL
2	Received during the quarter	NIL
3	Disposed off during the quarter	NIL
4	Remaining unresolved at the end of the quarter	NIL

NOTES :

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 11th November 2023.
- 2 The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies (Indian Accounting Standard) Rules 2015, and other recognised accounting principles generally accepted in India.

By Order of the Board  
for DOLPHIN MEDICAL SERVICES LIMITED

Place: Hyderabad  
Date : 11.11.2023



Dr. MOHAN PRASAD GV  
Managing Director  
DIN: 01236113

# DOLPHIN MEDICAL SERVICES LIMITED

Regd. Office: #417, Sanali Heavens, Ameerpet, HYDERABAD - 500 073, Telangana

CIN: L24239TG1992PLC014775, email: dolphincomplianceofficer@gmail.com

## Un Audited Statement of Assets and Liabilities as at 30.09.2023

(Amount Rs. In lakhs)

S. No.	Particulars	As at 30.09.2023 (Current period end) (Un Audited)	As at 30.09.2022 (Current period end) (Un audited)	As at 31.03.2023 (Current year end) (Audited)
	<b>Assets</b>			
1	<b>Non-current assets</b>			
	Property, plant and equipment	284.791	290.502	287.366
	Capital work-in-progress	30.665	30.665	30.665
	Goodwill	-	-	-
	Other intangible assets	-	-	-
	Intangible assets under development	378.484	378.484	378.484
	<b>Non-current financial assets</b>			
	Non-current investments	41.000	41.000	41.000
	Loans, non-current	281.950	281.950	281.950
	<b>Total non-current financial assets</b>	<b>322.950</b>	<b>322.950</b>	<b>322.950</b>
	Other non-current assets	1.350	1.350	1.350
	<b>Total non-current assets</b>	<b>1,018.240</b>	<b>1,023.951</b>	<b>1,020.815</b>
2	<b>Current assets</b>			
	Inventories	1.422	1.396	0.396
	<b>Current financial asset</b>			
	Current investments	-	-	-
	Trade receivables, current	-	-	-
	Cash and cash equivalents	2.697	1.803	1.274
	Bank balance other than cash and cash equivalents	0.095	0.101	0.102
	Loans, current	194.707	194.707	194.707
	<b>Total current financial assets</b>	<b>197.499</b>	<b>196.611</b>	<b>196.083</b>
	Other current assets	-	-	-
	<b>Total current assets</b>	<b>198.921</b>	<b>198.007</b>	<b>196.479</b>
3	Non-current assets classified as held for sale	-	-	-
	Regulatory deferral account debit balances and related deferred tax Assets	-	-	-
	<b>Total assets</b>	<b>1,217.161</b>	<b>1,221.958</b>	<b>1,217.294</b>
	<b>Equity and liabilities</b>			
1	<b>Equity</b>			
	<b>Equity attributable to owners of parent</b>			
	Equity share capital	1,509.995	1,509.995	1,509.995
	Other equity	(489.693)	(483.691)	(492.260)
	<b>Total equity attributable to owners of parent</b>	<b>1,020.302</b>	<b>1,026.304</b>	<b>1,017.735</b>
	Non controlling interest	-	-	-
	<b>Total equity</b>	<b>1,020.302</b>	<b>1,026.304</b>	<b>1,017.735</b>
2	<b>Liabilities</b>			
	<b>Non-current liabilities</b>			
	<b>Non-current financial liabilities</b>			
	Borrowings, non-current	76.523	71.318	75.523
	Other non-current financial liabilities	-	-	-
	<b>Total non-current financial liabilities</b>	<b>76.523</b>	<b>71.318</b>	<b>75.523</b>
	Provisions, non-current	-	-	-
	Deferred tax liabilities (net)	58.254	57.556	58.254
	Other non-current liabilities	-	-	-
	<b>Total non-current liabilities</b>	<b>134.777</b>	<b>128.874</b>	<b>133.777</b>
	<b>Current liabilities</b>			
	<b>Current financial liabilities</b>			
	Borrowings, current	-	-	-
	Trade payables, current	-	-	-
	Other current financial liabilities	62.082	66.780	65.782
	<b>Total current financial liabilities</b>	<b>62.082</b>	<b>66.780</b>	<b>65.782</b>
	Other current liabilities	-	-	-
	Provisions, current	-	-	-
	<b>Total current liabilities</b>	<b>62.082</b>	<b>66.780</b>	<b>65.782</b>
	Liabilities directly associated with assets in disposal group classified as held for sale	-	-	-
3	Regulatory deferral account credit balances and related deferred tax liability	-	-	-
4		-	-	-
	<b>Total liabilities</b>	<b>196.859</b>	<b>195.654</b>	<b>199.559</b>
	<b>Total equity and liabilities</b>	<b>1,217.161</b>	<b>1,221.958</b>	<b>1,217.294</b>

By order of the Board  
for DOLPHIN MEDICAL SERVICES LIMITED

Place: Hyderabad  
Date : 11.11.2023



**Dr. MOHAN PRASAD GV**  
Managing Director  
DIN: 01236113

# DOLPHIN MEDICAL SERVICES LIMITED

Regd.Office: #417, Sanali Heavens, Ameerpet, HYDERABAD - 500 073, Telangana

CIN: L24239TG1992PLC014775, email: dolphincomplianceofficer@gmail.com

## Un Audited Cash Flow Statement for the period ended 30.09.2023

(Amount Rs. In lakhs)

Particulars	30.09.2023 (Un Audited)	30.09.2022 (Un Audited)	31.03.2023 (Audited)
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Net Profit/(Loss) before tax	2.567	(3.891)	(11.762)
Adjustment For			
Depreciation	2.575	3.136	6.272
Proposed Dividend	-	-	-
Profit/Loss on Fixed Assets/Investments	-	-	-
Interest & Finance Charges	0.480	0.464	0.929
Prel. Exp.W/o	-	-	-
<b>Operating Profit/(Loss) before working capital charges</b>	<b>5.622</b>	<b>(0.291)</b>	<b>(4.561)</b>
Adjustment For			
Increase/ Decrease in inventory	(1.026)	(1.155)	(0.155)
Increase/ Decrease in Loans & Advances	-	-	-
Increase/ Decrease in Other Non Current Assets	-	-	-
Increase/ Decrease in Trade payables	-	-	-
Increase/ Decrease in Trade Receivables	-	-	-
Increase/ Decrease in Current Financial Liabilities	(4.180)	(0.729)	(2.192)
<b>Cash generated from operations (A)</b>	<b>0.416</b>	<b>(2.175)</b>	<b>(6.908)</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>			
Purchase of Fixed Assets	-	-	-
Increase/Decrease in Capital Work in Progress	-	-	-
Sale of Fixed Assets	-	-	-
Purchase of Investment	-	-	-
Sale of Investment	-	-	-
Interest received	-	-	-
Dividend received	-	-	-
Finance Charges paid	-	-	-
<b>Net cash flow from investing activities (B)</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>CASH FLOW FROM FINANCIAL ACTIVITIES</b>			
Proceeds from Convertible Share Warrants	-	-	-
Proceeds from Borrowings	1.000	2.906	7.111
Payment of Borrowings	-	-	-
Dividend paid	-	-	-
Increase/Decrease in Intangible Assets	-	-	-
<b>Net cash used in Financing Activities (C)</b>	<b>1.000</b>	<b>2.906</b>	<b>7.111</b>
<b>Net Increase /(Decrease) incash and cash equivalents (A+B+C)</b>	<b>1.416</b>	<b>0.731</b>	<b>0.203</b>
Cash and Cash equivalents as at previous year	1.376	1.173	1.173
Cash and Cash equivalents as at current year	2.792	1.904	1.376

By order of the Board  
for **DOLPHIN MEDICAL SERVICES LIMITED**

Place: Hyderabad  
Date : 11.11.2023



**Dr. MOHAN PRASAD GV**  
Managing Director  
DIN: 01236113

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE  
2<sup>nd</sup> QUARTER AND SIX MONTHS ENDED 30<sup>th</sup> SEPTEMBER 2023**

Review Report to  
The Board of Directors  
**M/s. Dolphin Medical Services Limited**  
#417, Sanali Heavens, Ameerpet  
**HYDERABAD** – 500 073

We have reviewed the accompanying statement of unaudited financial results of M/s. Dolphin Medical Services Limited for the 2<sup>nd</sup> Quarter and Six Months ended 30<sup>th</sup> September 2023 (“the Statement”), being submitted by the Company pursuant to the requirement of the Regulation 33 of The SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.

This Statement, which is responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial reporting” (“Ind AS 34”), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date : 11.11.2023



for **PINNAMANENI & Co.**,  
Chartered Accountants  
(Firm Registration No.002661S)



**CA P.V.V. SATYANARAYANA**  
Partner  
Membership No. 26600